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Abstract
To investigate the underlying causes of chemoresistance in malignant pleural mesotheli-
oma, we have studied mesothelioma cell lines as 3D spheroids, which acquire increased
chemoresistance compared to 2D monolayers. We asked whether the gene expression of
3D spheroids would reveal mechanisms of resistance. To address this, we measured gene
expression of three mesothelioma cell lines, M28, REN and VAMT, grown as 2D monolay-
ers and 3D spheroids. A total of 209 genes were differentially expressed in common by the
three cell lines in 3D (138 upregulated and 71 downregulated), although a clear resistance
pathway was not apparent. We then compared the list of 3D genes with two publicly avail-
able datasets of gene expression of 56 pleural mesotheliomas compared to normal tissues.
Interestingly, only three genes were increased in both 3D spheroids and human tumors:
argininosuccinate synthase 1 (ASS1), annexin A4 (ANXA4) and major vault protein (MVP);
of these, ASS1 was the only consistently upregulated of the three genes by qRT-PCR. To
measure ASS1 protein expression, we stained 2 sets of tissue microarrays (TMA): one with
88 pleural mesothelioma samples and the other with additional 88 pleural mesotheliomas
paired with matched normal tissues. Of the 176 tumors represented on the two TMAs,
ASS1 was expressed in 87 (50%; staining greater than 1 up to 3+). For the paired samples,
ASS1 expression in mesothelioma was significantly greater than in the normal tissues.
Reduction of ASS1 expression by siRNA significantly sensitized mesothelioma spheroids
to the pro-apoptotic effects of bortezomib and of cisplatin plus pemetrexed. Although meso-
thelioma is considered by many to be an ASS1-deficient tumor, our results show that ASS1
is elevated at the mRNA and protein levels in mesothelioma 3D spheroids and in human
pleural mesotheliomas. We also have uncovered a survival role for ASS1, which may be
amenable to targeting to undermine mesothelioma multicellular resistance.
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Introduction
Uncovering the causes of chemoresistance of tumors may help to develop effective therapies
aimed at undermining their survival strategies. Solid tumors are characterized by a 3D environ-
ment that may help cancer cells acquire new biological properties, such as resistance to cell
death and independence from growth factors and nutrients. Indeed, malignant mesothelioma,
a 3D mass that develops from a 2D pleural monolayer, may derive some of its chemoresistance
from its 3D morphology [1, 2]. Interestingly, the presence of 3D aggregates (spheroids) in pleu-
ral fluid is considered a characteristic of mesothelioma [3]. We believe that to devise improved
treatments for malignant mesothelioma, it may be helpful to understand how the 3D environ-
ment supports its chemoresistance.
We have previously shown that mesothelioma cells acquire additional resistance to apopto-
sis when grown in 3D, a property termed multicellular resistance. To date we have found that
multicellular resistance can be overcome by interfering with the mTOR pathway and the Bcl-2
repertoire, either by inhibition of anti-apoptotic proteins [4] or by activation of pro-apoptotic
ones [5]. Here, we asked whether a specific genetic signature, expressed by cells in 3D, could
offer insights into the molecular reprogramming that mediates additional apoptotic resistance.
It is known that spheroids alter their gene expression pattern when compared to their mono-
layer counterparts [6]; nonetheless, a connection to multicellular resistance has not yet
emerged.
Several studies have described the gene expression profile of mesothelioma [7–10]. It is well
known that mesothelioma is characterized by NF2 and BAP1 loss [11] and that there is prog-
nostic and diagnostic value in specific gene patterns [12–15]; nonetheless, no signature corre-
lated to a specific chemoresistance pathway has been found. To answer this question, we have
utilized 3D models to determine which genes are potentially implicated in multicellular resis-
tance. To narrow down our results and identify genes that are clinically relevant, we compared
our 2D-3D dataset with gene expression profiles of patient tumors compared to normal tissues.
In the present work, we demonstrate for the first time that ASS1 is upregulated in mesotheli-
oma 3D spheroids, is expressed in mesothelioma tumor samples, and exhibits a survival role.
Initially, this result was surprising, because mesothelioma is described in the literature as an
ASS1-deficient tumor [16–20], whose auxotrophy for arginine can be targeted therapeutically
[18]. Nonetheless, our data shows that ASS1 is a mesothelioma gene, as also described by Mel-
aiu and colleagues [9, 10], is upregulated when mesothelioma cells, but not normal mesothelial
cells, are grown as 3D spheroids, and that reduction of ASS1 protein levels has potential thera-
peutic value.
Results
Gene-expression changes found in 3D were associated with multiple
pathways
To identify genes that are differentially expressed between monolayers and spheroids, we per-
formed a microarray analysis of three mesothelioma cell lines (two epithelial, M28 and REN,
and one sarcomatous, VAMT) grown in 2D and in 3D. We identified a total of 209 differen-
tially expressed genes in all cell lines (Fig 1), of which 138 were upregulated (S1 Table) and 71
were downregulated (S2 Table). We used the Ingenuity Pathway Analysis platform to investi-
gate the functional associations of these 209 differentially expressed genes. Among the top
enriched molecular and cellular functions were pathways of cellular growth and differentiation,
cellular development, and cell, tumor and tissue morphology (S3 Table). These results were
confirmed by analysis using the Database for Annotation, Visualization and Integrated
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Discovery (DAVID), which showed the most significant enrichment in regulation of cell prolifera-
tion (GO:0042127) and wound healing (GO:0042060) (S4 Table). Although the pathways affected
by the differentially expressed genes might be associated with chemoresistance, it was difficult to
know how to study these pathways further. Instead, we decided to narrow the list of differentially
expressed genes to identify those 3Dmesothelioma genes with potential relevance in patients.
ASS1, ANXA4 and MVP are elevated in both 3D spheroids and patients
To uncover clinically relevant genes, we cross-referenced our list of differentially expressed
genes to two publicly available datasets (Gordon et al.,[21]—Singhal et al.,[22]) comprising the
gene expression profiles of 56 mesotheliomas (40 and 16 respectively) compared to 14 normal
tissue samples (9 and 5, respectively). By comparing these datasets, we found 3 genes that were
elevated in 3D compared to 2D as well as in mesothelioma compared to normal tissue: argini-
nosuccinate synthetase 1 (ASS1), annexin A4 (ANXA4) and the major vault protein (MVP).
We then validated the up-regulation of these genes by qRT-PCR. Of the three genes, ASS1
was the only gene confirmed to be upregulated in the three cell lines, M28, REN and VAMT
(Fig 2). Interestingly, ASS1 is thought to be deficient in mesothelioma. In fact, many
Fig 1. More than 200 genes are differentially expressed in mesothelioma spheroids compared to
monolayers. Venn diagrams showing the number of genes differentially expressed by spheroids of three
mesothelioma cell lines M28, REN and VAMT, compared to respective monolayers. The diagram also shows
the number of genes upregulated (138) and downregulated (71) in common by the three cell lines.
doi:10.1371/journal.pone.0150044.g001
Fig 2. ASS1 gene expression is upregulated in 3D spheroids andmesothelioma patients. qRT-PCR results showing the Log2-transformed fold change
in gene expression for ASS1, ANXA4 and MVP between M28, REN and VAMT spheroids and monolayers. Results were normalized to the gene expression
levels of monolayers (gray line). Only ASS1 was upregulated in 3D in all three cell lines. (* p 0.05 n = 3).
doi:10.1371/journal.pone.0150044.g002
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publications describe mesothelioma as an ASS1-deficient tumor [16–20], and thus one that can
be targeted with arginine deiminase (ADI), an enzyme that degrades arginine [18]. Hence, to
confirm our findings, we analyzed ASS1 expression at the protein level in both mesothelioma
spheroids and patient samples.
ASS1 protein is increased in 3D spheroids and expressed in tissues
To confirm the upregulation of ASS1 protein levels in spheroids, we investigated various anti-
bodies because the antibody that has been widely used for the detection of ASS1 had been dis-
continued (BD, clone 25). Hence, we tested a panel of antibodies currently available for ASS1:
the discontinued clone 25 [23] and newer clones 2B10 and 2C10. As positive and negative con-
trols for ASS1, we used MSTO-211H transduced with ASS1 (MSTO-pIRES-ASS1) and with an
empty vector (MSTO-pIRES-EV). We found that staining for both clone 25 and clone 2B10
was non-specific (especially BD clone 25), while clone 2C10 correctly identified ASS1 in trans-
duced MSTO cells (Fig 3A). Therefore, we used clone 2C10 ASS1 antibody for detecting ASS1
protein in spheroids and in tumor.
We performed immunoblots on monolayers and spheroids generated fromM28, REN and
VAMT cells, the cell lines used in our microarray analysis. To these, we added three more cell
lines (SARC, JMN and MSTO-211H), one of these known to be ASS1-negative (MSTO-211H).
Four of the cell lines showed increased ASS1 protein levels in 3D compared to 2D, while two of
them (JMN and MSTO-211H) lacked expression of ASS1 altogether (Fig 3B). Our findings
suggest that cells capable of expressing ASS1 elevate its protein levels in 3D, whereas the cells
with ASS1 deficiency do not. Interestingly, normal mesothelial cells did not upregulate ASS1 in
3D (Fig 3C).
To investigate the levels of ASS1 protein expression in human mesothelioma tumors, we
performed immunohistochemistry on 2 sets of tissue microarrays (TMA) containing samples
from 176 pleural mesotheliomas. In the first set of 88 mesotheliomas, only 8 mesotheliomas
completely lacked ASS1 expression (Fig 4A). In another set of clinical samples, which con-
tained 88 tumors along with their matching normal control tissue, ASS1 was significantly upre-
gulated in mesothelioma samples compared to their matched normal controls (Fig 4B).
Among the 88 mesotheliomas, there was no difference in ASS1 expression between epithelioid
(n = 46) and non-epithelioid (sarcomatous and biphasic)(n = 42) mesotheliomas (S5 Table). In
all 176 tumor samples, ASS1 protein was expressed in 87 (50%; more than 1+).
ASS1 has a survival role in cells in which it is expressed
The lack of ASS1 expression has been associated with resistance to platinum [24], suggesting
that ASS1 could enhance chemosensitivity. On the other hand, we have found ASS1 upregu-
lated in 3D spheroids and tumor samples and we hypothesized that it could be associated with
increased chemoresistance (multicellular resistance). Thus, to clarify whether ASS1 was associ-
ated with chemosensitivity or chemoresistance, we performed RNAi experiments and mea-
sured the response to chemotherapy of spheroids in the absence of ASS1 expression. ASS1
siRNA effectively reduced ASS1 expression in 3 cell lines (M28, SARC, and VAMT) with base-
line ASS1 expression (Fig 5A). In these cell lines, but not in MSTO, which do not express ASS1,
reduction of ASS1 expression led to increased apoptosis. Also, in these cells, but not in ASS1--
deficient MSTO, the reduction of ASS1 increased the apoptotic response to bortezomib and to
cisplatin plus pemetrexed, indicating that ASS1 has survival roles in 3D and thus may contrib-
ute to chemoresistance (Fig 5B).
ASS1 Is Upregulated in Mesothelioma 3D Spheroids and Tumors
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Discussion
Multicellular resistance, the resistance acquired by cells in 3D, may mimic the chemoresistance
of solid tumors [25]. In mesothelioma, we have investigated contributions of the PI3K/Akt
pathway [26, 27] and the Bcl-2 family [28] to multicellular resistance and have found strategies
to bypass such resistance mechanisms [1, 4, 5]. With this study, we asked whether a 3D gene
signature could give insights into the source of multicellular resistance. Indeed, spheroids have
been shown to represent the gene expression of their original tissue better than monolayers
[29] and have been used to identify tumor-relevant genes associated with survival [30]. Using
this screening approach, in which genes upregulated in 3D were cross-referenced against pub-
lished mesothelioma genes, we found that ASS1 is upregulated in 3D and also in mesothelioma.
This result was unexpected because, in the literature, mesothelioma has been described as an
ASS1-deficient tumor [16–20]. Thus, there appear to be two groups of mesothelioma, those
with ASS1 deficiency and those with upregulation of ASS1.
ASS1 represents the rate-limiting enzyme in the production of arginine, a semi-essential
amino acid for multiple metabolic and synthetic functions [18, 31, 32]. However, in certain
tumors, ASS1 has been found to be deficient [33], likely due to promoter methylation [19, 34].
Without ASS1, cells are dependent on extracellular arginine, a condition known as arginine
auxotrophy. In this situation, the ASS1-deficient tumor is vulnerable to strategies that target
this lifeline; accordingly, treatments to degrade extracellular arginine are being used in the
patients with ASS1-deficient tumors. Such tumors have been reported to include melanoma,
hepatocellular carcinoma, renal cell carcinoma, prostate cancer and mesothelioma [17]. ASS1
deficiency has also been associated with platinum resistance; in some studies, the silencing of
ASS1 has induced a resistance to platinum-induced cell death while, at the same time, sensitiz-
ing to arginine degradation [24]. In the case of mesothelioma with low ASS1 expression,
patients have been treated with pegylated arginine deiminase (ADI-PEG20), either alone
(ADAM - https://goo.gl/hSNkI7)) or together with chemotherapy (TRAP - http://goo.gl/
tiwzGO), to deprive the tumor of arginine; results from these trials are pending.
In our study, ASS1 emerged as strongly associated with the 3D phenotype, which itself is
associated with chemoresistance. In addition, when tissue microarrays were examined, ASS1
protein expression was also found to be elevated in many mesothelioma tumors. In paired sam-
ples, ASS1 was elevated in tumor compared to adjacent normal tissues. Thus, ASS1 appears to
be a gene relevant to mesothelioma biology, with a significance as yet unknown. Other studies
have also identified the presence of ASS1 in mesothelioma; in one review of transcriptome
studies, ASS1 gene was one of the most prominently increased genes in mesothelioma [9]. In
addition, in the first report of ASS1 protein expression in mesothelioma, 63% of mesotheliomas
were found to have low expression (0–1+) while 37% had high expression (2–3+). Our find-
ings, if we combine all our tumors, would be 50:50; in 176 tumors, 89 demonstrate low expres-
sion (0–1+) and 87 demonstrate moderate to high (greater than 1 to 3+). Although differences
can be due to different antibodies or technique, both of our studies suggest that a significant
Fig 3. ASS1 protein is upregulated in 3D in mesothelioma cells but not in normal mesothelial cells. (A) ASS1 antibodies (BD clone 25, Sigma clone
2B10, and Millipore clone 2C10) were tested against ASS1-positive MSTO pIRES-ASS1 (as a positive control) and ASS1-negative MSTO pIRES-EV (as a
negative control). Monoclonal antibody clone 2C10 provides the most accurate detection of ASS1 protein levels. (B) Immunoblot analysis of ASS1, ANXA4
and MVP in monolayers (m) and spheroids (s) grown from 6 mesothelioma cell lines (M28, SARC, VAMT, REN, JMN) and MSTO-211H (known to be
ASS1-negative). MSTO pIRES-ASS1 cells were used as positive control for ASS1. ASS1 was the most consistently upregulated in 3D among the panel of
cells tested. JMN and MSTO cells showed no ASS1 expression. (C) Immunoblot analysis of ASS1 in normal mesothelial cells grown as monolayers and
spheroids. ASS1-negative MSTO pIRES-EV and ASS1-positive MSTO pIRES-ASS1 were used as controls for ASS1. Normal mesothelial cells did not
upregulate ASS1 when grown in 3D.
doi:10.1371/journal.pone.0150044.g003
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number of patients with mesothelioma will have elevated ASS1 expression. Thus, while ASS1
deficiency is undoubtedly of interest in this tumor, ASS1 overexpression also merits attention.
The role of ASS1 in tumor biology has been confusing, with ASS1 thought to act either as a
tumor suppressor [35] or as pro-metastatic or carcinogenic [36]. We propose that the function
of ASS1, a gene whose expression increases in 3D, may better be studied in 3D. In our 3D
spheroids, ASS1 showed a survival role. The reduction of ASS1 protein by siRNA led to an
increased sensitivity to chemotherapy, including to cis-platinum. We speculate that ASS1 upre-
gulation is in response to an increased need or decreased supply of arginine in 3D and in the
tumor and would be a logical step in promoting survival of the tumor cells. If so, then tech-
niques to suppress ASS1 could improve response to chemotherapy and would also render the
tumor vulnerable to arginine depletion techniques [23], such as ADI-PEG20. Further studies
are underway to identify small molecules or other strategies to inhibit ASS1 both to understand
its function in mesothelioma and to provide possible therapeutic options to patients with high
ASS1 expression.
Methods
Cell culture and reagents
The human mesothelioma cell lines M28 [37] and VAMT [38] (both from Dr. Brenda Gerwin,
NCI, National Institutes of Health, Bethesda, MD, USA), REN [39] (from Dr. Roy Smythe,
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA), SARC [40] (MesoSA1
–from Dr. Alice Boylan, Medical University of South Carolina, Charleston, MC, USA), JMN
[41] and MSTO-211H [ATCC1 CRL-2081™] (both from Dr. Dean Fennell, University of
Leicester, UK), MSTO pIRES-EV and MSTO pIRES-ASS1 [24] (both kindly donated by Dr.
Peter Szlosarek, Barts Cancer Institute, Queen Mary University of London, UK), were all cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum in a 37°C humidified incubator with 5% CO2. All were found to stain positively for
mesothelioma markers (calretinin, WT1) and negatively for other markers not seen in meso-
thelioma (TTF1). Normal human mesothelial cells were cultured from ascites fluid from
unidentified patients without infection or malignancy according to a protocol (#12–08998)
approved by the University of California, San Francisco Committee on Human Research under
our BUA (BU031309-03) [42]. All cells were confirmed to be negative for mycoplasma every 2
months by PCR analysis as previously described [43]. Bortezomib was from Selleck Chem
(Boston, MA, USA). Cisplatin and pemetrexed were obtained from the University of Califor-
nia, San Francisco Pharmacy at Mt. Zion Cancer Center.
Generation and treatment of spheroids
Multicellular spheroids were generated in non-adsorbent round-bottomed 96-well plates
coated with a 1:24 dilution of polyHEMA (#P3932 Sigma-Aldrich, St. Louis, MO, USA) in 95%
ethanol and dried at 37°C for 48 h. Plates were sterilized with UV-light for 30 min before use.
In each well, 10,000 cells were added and plates were centrifuged at 1000 rpm for 5 min to con-
centrate the cells at the bottom and incubated for 24 h to allow formation into a solid spheroid.
Fig 4. ASS1 protein is expressed in mesothelioma samples and upregulated when compared to normal tissues. (A) ASS1 stain intensity was
measured in 88 mesothelioma samples by immunohistochemistry (each tumor in replicates of 3) in a semi-quantitative fashion as outlined in the Methods
section. Only 8 samples out of 88 (10%) showed no ASS1 staining (B) ASS1 stain intensity was also measured in another 88 mesotheliomas with their paired
88 normal tissues. Analysis of matched pairs (tumor vs normal tissue control obtained from the same patients) of the 88 patients showed that ASS1
expression was significantly higher in mesothelioma (* p < 0.0001, n = 88 matched pairs).
doi:10.1371/journal.pone.0150044.g004
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Before treatment, 24 multicellular spheroids were transferred to each well of a polyHEMA-
coated 24-well and treated for 24 h unless stated otherwise.
Microarray
Sample preparation, RNA extraction/amplification, labelling, and array hybridizations were
performed according to standard protocols from the UCSF Shared Microarray Core Facilities
([44], http://arrays.ucsf.edu/protocols). A total of 18 samples (three for monolayers and three
for spheroids for each cell line) were analyzed. Labeled cRNAs were hybridized to 70-mer oli-
gonucleotides microarrays produced using the Operon Human Genome 70-mer Oligo Set Ver-
sion 2.0 (Operon Biotechnologies, Huntsville, AL). Additional information about microarray
protocols and the complete array data are available from Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo/, series accession GSE4804). Expression profiling of monolayers
and spheroids for M28, REN and VAMTmesothelioma cells was carried out using three bio-
logical replicates in each cell type and two technical replicates (Cy3/Cy5 dye-swap replicates)
for each sample. The data were normalized using robust locally weighted regression (loess) to
correct for intensity, spatial and other dye biases [45, 46]. The differential expression of genes
in spheroid with respect to monolayer was analyzed using the BioConductor LIMMA package
[http://www.bioconductor.org]. We estimated the mean log-ratios and calculated moderated t-
statistic, B statistic, false discovery rate and p-value for each gene for the direct comparisons
between monolayers and spheroids. P values were adjusted for multiple testing using Bonfer-
roni correction. In order to have the broadest selection of genes to compare the 3 cell types, we
selected candidate differentially-expressed genes using adjP< 0.05 without cutoffs on fold-
change. Genes were considered upregulated when the log2 ratio (M value) was> 0 (i.e. fold-
change between the conditions of interest> 1); genes were considered downregulated when
the log2 ratio< 0 (i.e. fold-change< 1).
Gene Ontology analysis
The Ingenuity Interactive Pathway Analysis of Complex ‘Omics Data platform was used to
investigate the functional associations between differentially expressed genes. Analysis was per-
formed by the CNRS and University Nice Sophia Antipolis, IPMC, Valbonne, France. We also
interrogated the Database for Annotation, Visualization and Integrated Discovery (DAVID)
functional annotation tool (http://david.abcc.ncifcrf.gov) by using the full list of differentially
expressed genes in 3D.
Real-Time qRT-PCR
RNA was extracted from monolayers (1 million cells) or spheroids (100 spheroids) with an
RNeasy Kit following manufacturer’s instructions (Qiagen, Valencia, CA, USA). Total RNA
was quantified with a NanoDrop 2000c (NanoDrop, Wilmington, DE, USA) and 2 μg of total
RNA was retro-transcribed with a Superscript VILO cDNA Synthesis Kit (Life Technologies,
Carlsbad, CA, USA). A TaqMan Gene Expression Analysis Assay (Life Technologies, Carlsbad,
CA, USA) was performed according to manufacturer’s instructions in an ABI7000 thermal
Fig 5. ASS1 knockdown by siRNA increases the chemosensitivity of spheroids. (A) Immunoblot analysis of M28, SARC, VAMT and ASS1-deficient
MSTO spheroids, transfected with siRNA targeting ASS1 or control sequences show that ASS1 was efficiently knocked down in all the cells where it was
expressed. (B) Apoptotic rates were measured for M28, SARC, VAMT and MSTO spheroids transfected with siRNA targeting ASS1 or control sequences
and treated with bortezomib (BZ, 25 nM) or cis-platinum (200 μM) plus pemetrexed (10 μM)(C+P). In the 3 cell lines with baseline ASS1 expression, ASS1
siRNA increased the basal apoptotic rate and also increased the apoptotic response to chemotherapy. ASS1 siRNA had no effect in the ASS1-deficient
MSTO spheroids. Apoptosis was quantified in a blinded fashion by assessing nuclear condensation in Hoechst-stained cells. (* p 0.05 n = 3).
doi:10.1371/journal.pone.0150044.g005
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cycler (Life Technologies, Carlsbad, CA, USA). TaqMan probes for ASS1 (Hs01597989_g1),
ANXA4 (Hs00984874_m1), MVP (Hs00245438_m1) and the control beta glucuronidase
(GUSB, 4333767T) were from Applied Biosystems (Life Technologies, Carlsbad, CA, USA).
Calculations for determining the relative levels of gene expression were made from triplicate or
quadruplicate measurements of the target gene, with normalization to GUSB in the samples,
using the cycle threshold (Ct) method and the 2^-ddCT equation [47].
SDS-PAGE and immunoblotting
Monolayers and spheroids were lysed in boiling lysis buffer (2.5% SDS, Tris-HCl 250 mM pH
7.4) and protein concentration was determined using a colorimetric assay (DC protein assay
from BioRad, Hercules, CA, USA). 30 μg of protein was supplemented with Laemmli sample
buffer and separated on an SDS-PAGE gel. Proteins were transferred to PVDF membranes
(Immobilon, Millipore, Billerica, MA, USA) and blocked with 5% Blotto (Santa Cruz Biotech-
nology, Dallas, TX, USA) in PBS. Primary antibodies were diluted in 5% non-fat dry milk or
5% BSA. The following primary antibodies were used: anti-ASS1 (clone 25, 1:500, BD Biosci-
ences, San Jose, CA, USA; clone 2B10, 1:500, Sigma-Aldrich, St. Louis, MO, USA; clone 2C10,
1:500, Millipore, Billerica, MA, USA), anti-α-tubulin (#A5441, 1:10,000, Sigma-Aldrich,
St. Louis, MO, USA). Secondary antibodies were from BioRad (Hercules, CA, USA). Chemilu-
minescence was detected with the enhanced SuperSignal West Pico Substrate (Pierce, Rock-
ford, IL, USA) with a Biospectrum Imaging System (UVP, Upland, CA, USA).
Human subjects research
The University of California San Francisco CHR approved the studies on human samples
under an exempt category (#12–08998). CHR protocol 12–08998 was reviewed by the Univer-
sity of California San Francisco Committee on Human Research, Laurel Heights Committee
(CHR FWA number: 00000068; IRB registration number: 00003471). Exemption was granted
because the research involves the collection or study of existing data, documents, records, path-
ological specimens, or diagnostic specimens or because the information is recorded by the
investigator in such a manner that subjects cannot be identified, directly or through identifiers
linked to the subjects. Both of these statements were met in our research. Moreover, the coded
private information or specimens were not collected specifically for the current proposed
research project and the key to decipher the code is destroyed before researcher begins. Sam-
ples were obtained from surgeries performed by Dr. Raphael Bueno, Chief, Division of Tho-
racic Surgery at Brigham and Women's Hospital, Boston MA with consent from Dana Farber/
Harvard Cancer Center IRB-approved protocol 98–063. The University of California San Fran-
cisco CHR committee approved the use of these unidentified mesothelioma samples for our
research. Normal mesothelial cells were obtained under the same CHR-exempt authorization
from unidentified patients' material (ascites or pleural fluid) that would otherwise be discarded.
Clinical tumor micro arrays, obtained under the same CHR protocol (12–08998), were created
by the pathology core facilities of the Dana Farber/Harvard Cancer Center, with coded links to
patient identity under protocol 98–063
Immunohistochemistry
We utilized 2 sets of tumor microarrays (TMA): one set contained 88 chemonaïve mesotheli-
oma samples (created by the Pathology Core facility at University of California San Francisco,
Mt. Zion with anonymous mesothelioma samples obtained from our collaboration with Drs.
Bueno and Richards) and one set contained a different 88 mesotheliomas with matching nor-
mal tissue, created from clinical pathology blocks of Brigham and Women's Hospital patients.
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In addition to anonymous control cores, microarray blocks contained, per included patient, 3
cores of tumor and, if available, 3 cores of normal tissue obtained from selected areas of archi-
val clinical blocks. Sections of TMAs (5 μm) were stained for 2 h at RT with antibodies for
ASS1 (clone 2C10, 1:1000, Millipore, Billerica, MA, USA) and visualized with a HRP/DAB
Envision plus Kit (#K4010, Dako, Carpinteria, CA). Known negative and positive controls
were included. Hematoxylin was used as a counterstain. Slides were viewed by two independent
scorers and scored semi-quantitatively (0 = no staining, 1 = weak staining, 2 = moderate stain-
ing, 3 = strong staining) [18].
Nuclear condensation assay by Hoechst staining
Spheroids were disaggregated with trypsin, washed with ice-cold PBS, and then fixed with 2.5%
glutaraldehyde (Sigma-Aldrich, St. Louis, MO, USA). Cells were then stained with 8 mg/ml of
Hoechst 33342 (Molecular Probes, Life Technologies, Carlsbad, CA, USA) and placed on slides.
Apoptosis was quantitated by counting cells with distinctive signs of nuclear condensation and
expressed as a % of the total cells. For each condition, at least 300 cells were counted in tripli-
cate by investigators blinded to the experimental conditions. We have found that this assay is
more accurate than assays that detect surface phosphatidylserine in cells disaggregated from
spheroids [1].
RNA interference
Transient knockdowns were performed using Lipofectamine RNAiMAX according to the man-
ufacturer’s protocol (Life Technologies, Carlsbad, CA, USA). In brief, cells were transfected in
Opti-MEM (Life Technologies, Carlsbad, CA, USA) and allowed to grow as monolayers for
24 h in complete DMEMmedium. Cells were then trypsinized, counted, plated in polyHEMA
plates and allowed to form spheroids for 24 h. Spheroids were then treated as described in fig-
ure legends, between 48 and 72 h from transfection. The human argininosuccinate synthetase 1
(ASS1) siRNA (Stealth HSS181354, 5’-AGC AGC UGA GCU CAA ACC GGA CCU-3’) and
the Stealth siRNA Negative Control lo GC (#12935) were purchased from Life Technologies,
Carlsbad, CA, USA.
Statistical analysis
Data are expressed as mean ± standard deviation of at least three different experiments. Statis-
tical significance was evaluated by ANOVA (with Tukey’s test to determine where the differ-
ence lay). Differences between the tumor and normal tissue matched pairs and between
epithelioid and non-epithelioid tumors were evaluated by the Mann-Whitney non-parametric
test. A p value 0.05 was considered significant. (GraphPad Prism v 4.0, GraphPad Software,
Inc., La Jolla, CA, USA).
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S1 File. Raw data for Figs 2, 4A and 4B and 5B.
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S1 Table. Upregulated genes in 3D. The table shows the 138 genes upregulated in 3D spher-
oids grown fromM28, REN and VAMT cell lines.
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S2 Table. Downregulated genes in 3D. The table shows the 71 genes downregulated in 3D
spheroids grown fromM28, REN and VAMT cell lines.
(PDF)
S3 Table. Ingenuity1 analysis of the genes differentially expressed by mesothelioma spher-
oids compared to respective monolayers. The table shows the top functions altered in 3D in
the signaling families:molecular and cellular functions, physiological system development and
function, and diseases and disorders. The pathways affected in the different categories are
shown in the table, together with p value and number of differentially expressed genes in each
pathway (Count). A comprehensive analysis of the functions affected by the differentially-
expressed genes did not reveal a single suppressed or activated pathway.
(PDF)
S4 Table. DAVID Analysis of the genes differentially expressed in 3D. The table shows the
DAVID functional annotation chart with p<0.01 for the differentially expressed genes in 3D.
(PDF)
S5 Table. ASS1 expression is not statistically different between epithelioid and non-epithe-
lioid mesotheliomas. The table shows the ASS1 staining intensity of 88 mesotheliomas, cate-
gorized by their histotypes: epithelioid (46) and non epithelioid (42—sarcomatous and
biphasic). The difference between the two groups was not statistically significant (p = 0.5662).
(PDF)
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